AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04192032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic Tobacco Juul pod flavor (5% nicotine)
Description: Classic Tobacco Juul pod flavor (5% nicotine)
Study NCT04192032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred flavor with HWL
Description: Preferred flavor (5% nicotine) with HWL
Study NCT04192032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred flavor, 3% nicotine
Description: Preferred flavor, 3% nicotine
Study NCT04192032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred flavor, 0% nicotine
Description: Preferred flavor, 0% nicotine
Study NCT01970592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWER training
Description: Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be \~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking
Study NCT03762525 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: ECG gated CTA
Description: Routine care consists of a preoperative and several postoperative CTA scans. In A. The preoperative and first postoperative CTA will be replaced by ECG-gated CTA imaging and in B. the scheduled imaging will be replaced by an ECG-gated CTA.~General information: The protocol is based on the ECG gated cardiac protocol using abdominal parameter settings.
Study NCT01520454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: IV saline at 0.83 mL/kg/hr for six hours
Study NCT01520454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Study NCT02913287 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aquamin/Aquamin MG
Description: Marine-based nutraceutical
Study NCT02913287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin Placebo
Description: Maltodextrin Placebo
Study NCT01520454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water
Description: Water by mouth
Study NCT01520454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water by mouth
Study NCT01520454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral fat
Description: Soybean oil by mouth at 1.25 g/kg x 2 doses
Study NCT01978015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost and timolol maleate fixed combination
Description: bimatoprost0.03% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
Study NCT01978015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dextran and hypromellose
Description: Dextran 70 and hypromellose, lubricant eye drop at 8 a.m and 8 p.m for 6 months
Study NCT01520454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
Study NCT01267136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine with acetaminophen
Description: Liquid codeine/acetaminophen (Capital® 5mL= 120mg acetaminophen/12 mg codeine) 0.72 mg/kg \[=0.3 mL/kg\] (max. 36 mg) PO Q6h, plus 0.72 mg/kg (max. 36 mg) PO Q3h pro re nata (PRN) (max. of 3 PRN doses/day)
Study NCT01267136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol suspension
Description: Liquid tramadol 1.05 mg/kg \[=0.3 mL/kg\] (max. 52.5 mg) PO Q6h, plus 1.05 mg/kg (max. 52.5 mg) PO Q3h PRN (max. of 3 PRN doses/day).
Study NCT01520454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparin
Description: Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
Study NCT04919473 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Therapy product:vMCO-I
Description: The vMCO-I is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
Study NCT00534586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: TCI 0.5 mcg/ml 1.0 mcg/ml
Study NCT00534586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: continuous infusion 0.05 mcg/kg/min 0.15 mcg/kg/min
Study NCT00534586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Ketamine
Description: continuous infusion 0.25 mg/kg/h 0.50 mg/kg/h
Study NCT00534586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: via face mask 0.40 Vol% 0.80 Vol%
Study NCT03027050 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-PRF
Description: Applied for treatment of periodontal bone loss.
Study NCT03027050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-PRF
Description: Applied for treatment of periodontal bone loss.
Study NCT03027050 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flap Debridement alone
Study NCT03027050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Flap Debridement alone
Study NCT02674828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement for meeting targeted physical activity goals
Description: Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
Study NCT02674828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it >2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
Study NCT02674828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it >2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
Study NCT04638673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix taVNS model 0125-LTE Stimulator - Active-Active Group
Description: Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.
Study NCT04488887 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography
Description: patients in all groups will be examined with optical coherence tomography angiography, for every eye 3 macular and 3 papillary scans will be performed by two different OCTA machines, analysis will be carried out to evaluate the repeatability and reproducibility of the test
Study NCT01045239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropulse 577 nm yellow diode laser
Description: Laser administered at beginning of study and may be repeated at 16 weeks if needed
Study NCT01045239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 532 nm green diode laser
Description: Laser administered at beginning of study and may be repeated at 16 weeks if needed
Study NCT02853214 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis of peripheral blood samples
Description: M.D investigators report the identified families with all the information: description of the familial area (for example: 2 cases father and son), last medical report for the case with the type of dysglobulinemia, monoclonal component isotype, medical background and contact information for one of the patients or cases with Name/surname/Date of Birth/address and phone. They contact the patient to explain the study and establish the family pedigree. They collect the information on all the family members and send to the patient a mail: an information note on the study, a prescription for the blood sample and the informed consents. They proceed in the same way for the relatives with the additional prescription: EIP. They organize the logistic in the medical lab or hospital chosen by the person. They receive 4 Heparin and 1 serum tubes for each and with this, they obtain a large amount of biological material for the genetic analysis thanks to the establishment of lymphoblastoid cell lines
Study NCT00903344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4000IU vitamin D3 tablet taken daily
Study NCT00903344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Multivitamin containing 400IU vitamin D in tablet taken daily
Study NCT03919019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macuprev Group
Description: oral supplementation (Macuprev) 2 capsules per day for 6 months
Study NCT03919019 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: oral placebo 2 capsules per day for 6 months
Study NCT02667561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1% 2.2 mg
Description: Application of 220 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
Study NCT04638673 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group
Description: Participants will receive sham taVNS stimulation for weeks 1\&2 and active stimulation for weeks 3\&4 of the stimulation portion of this study.
Study NCT03306862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole yellow pea soup
Description: Soup containing whole yellow peas
Study NCT03306862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Split yellow pea soup
Description: Soup containing split yellow peas
Study NCT03306862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Potato soup
Description: Soup containing potatoes
Study NCT01554397 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-guided Bone Marrow-Sparing Intensity Modulated Radiation Therapy (IMRT)
Description: IMRT 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks with PET-guided Bone Marrow-Sparing
Study NCT02667561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1% 4.4 mg
Description: Application of 440 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
Study NCT02667561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1% 8.8 mg
Description: Application of 880 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
Study NCT02667561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Testosterone Gel 1%
Description: Application of approximately 550 mg of Placebo of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
Study NCT04787016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilate training
Description: Pilates is an exercise training program used to build core strength and flexibility.
Study NCT03167658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace wellness program
Description: Multi-prong workplace wellness program, with components such as nutrition counseling, fitness challenges, and stress management workshops, including supports and incentives.
Study NCT01283945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Oral administration, once daily (qd), in fasting conditions.~Dose escalation - continuous schedule~Dose expansion - continuous or intermittent dosing schedules (i.e. 5 days on/2days off or 21 days on/7 days off)~Dosage form: hard gelatin capsules for oral administration (2.5, 5, 10, 30 and 50 mg strengths)
Study NCT00974532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High calcium diet 2000 mg/day
Description: High calcium (2000 mg elemental calcium) diet x 9 days
Study NCT00974532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High calcium diet 2000 mg/day
Description: High calcium (2000 mg elemental calcium) diet x 9 days
Study NCT00974532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low calcium diet, 800 mg/day
Description: Low calcium (800 mg elemental calcium) diet x 9 days
Study NCT00974532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low calcium diet, 800 mg/day
Description: Low calcium (800 mg elemental calcium) diet x 9 days
Study NCT01946269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Goal-directed Resuscitation Therapy (GDT)
Description: * A target value of a cardiac index (CI) greater than 2.5 L/min/m2 and a mean arterial pressure of 70 mmHg will be sought.~* The first step will be fluid resuscitation with 200ml aliquots of Lactated Ringer's solution plus human albumin 20% 50 mL whenever the CI is lower than 2.5 L/min/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period or CI increases less than 10%.~* When the CI is lower than or equal to 2.5L/min/m2 despite of fluid challenge, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~* The final step will be red blood transfusion to reach a hematocrit higher than 28%.~* If necessary, norepinephrine infusion will be used to maintain a mean arterial pressure above 70 mmHg.
Study NCT01946269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol
Description: The control group will be managed by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
Study NCT03362632 — intervention group
Intervention type: DRUG
Intervention: Antibiotics
Description: This is an observation study, no specific antibiotics will be indicated during treatment.
Study NCT01554397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks
Study NCT02532907 — intervention group
Intervention type: PROCEDURE
Intervention: Liver Biopsy
Description: patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.
Study NCT05524792 — intervention group
Intervention type: OTHER
Intervention: no interventional study
Description: no interventional study
Study NCT03113188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP501
Description: CBP501, CDDP plus Nivolumab
Study NCT01554397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks
Study NCT01554397 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks
Study NCT04157582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates training
Description: 1. Pilates warm-up training (5 minutes) consisted of Breathing, the Chest stretch, the Toy soldier, Upper extremity PNF patterns, and Roll down.~2. Pilates mat training performed in 5 different positions (30 minutes).~   1. One leg stretch, Hundreds, the Double leg stretch, Scissors, the Shoulder bridge, Oblique preparation, and the Hip twist were performed in the supine position(Fig.7).~  2. Clare, the Side kick, Arm openings, the Lower lift, Leg lifts, and the Side bend were performed in the side-lying position.~  3. Swan dive, the One leg kick, Swimming, the Breast stroke preparations, the Breast stroke performed in the prone position(Fig.8).~  4. Half roll back, Oblique roll up were performed in the sitting position.~  5. Swimming was performed in the kneeling position.~3. The Pilates cool down training (5 minutes) were the Spine stretch, Saw, Chest stretch, Toy soldier. (Cruz et al .,2011)
Study NCT04157582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: 1. Gentle manual stretching exercises for (elbow flexors, wrist flexors , hamstring and calf muscle).~2. Strengthening Exercises for ( elbow extensors, wrist extensors and dorsiflexors)~3. Balance training (Wobble board training) :~   * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror with hand support(with repetition 10times)~  * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror without hand support(with repetition 10times).
Study NCT00112385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept 50 mg will be injected subcutaneously once per week for 52 weeks
Study NCT00112385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, contained in 50mg syringes, will be injected subcutaneously once per week for 52 weeks.
Study NCT03733782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modular enteral protein - Prosource
Description: Supplemental protein (2 gm/kg/day of Prosource; Medtrition, Lancaster, PA) was administered via the nasal/oral feeding tube in 60 - 180 ml bolus infusions 2 - 4 times per day, independently of the enteral formula received. That is, the daily target amount of protein was initially administered as the supplement boluses and only after the enteral formula infusion approached the target rate was the amount of supplement decreased. Supplemental protein was reduced by 50% once the patient received 75% of targeted caloric intake over the previous day (0700 - 0700). Once the patient reached the target caloric intake for 48 hours, the amount of supplemental protein was decreased in order that the total protein prescribed equaled 2 gm/kg/day.
Study NCT05075473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental stabilization
Description: Physiotherapist will perform activation of multifidus in prone position. It also includes activation of transverse abdominas in crook lying position, in sitting as well as in point kneeling position to re-establish simultaneous contraction of deep muscles synergy.
Study NCT05075473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Generalized Lumber stabilization exercsies
Description: It can by performed by patient him or her self under physiotherapist's assistance. Lumber neutral position is maintained. Bridging in prone as well as supine position will be maintained.
Study NCT04021563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR419
Description: Ascending single and multiple doses of SR419 orally
Study NCT02595437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Study NCT02578537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor group:all patients receive ticagrelor (180 mg loading dose, then 90 mg twice daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
Study NCT02578537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel group:all patients receive clopidogrel (600 mg loading dose, then 75 mg once daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
Study NCT01832298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitecan Hydrochloride for Injection
Description: Either at 12.5 mg, 25 mg、50 mg、80 mg、120 mg、160 mg、200 mg
Study NCT00310843 — intervention group
Intervention type: DRUG
Intervention: Nevirapine
Description: Patients with HIV-1 infection who have taken or are currently taking nevirapine
Study NCT04245605 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary angiography
Description: Coronary angiogram performed either in hospital or post-discharge, within 14 days after initial hospital presentation with heart failure
Study NCT01380132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anal injection of Nasha Dx
Description: Submucous injection of Nasha Dx 5-10 mm above dentate line
Study NCT04021563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending single and multiple doses of placebo orally